Literature DB >> 20624641

Mechanisms of allergen-specific desensitization.

Christina Uermösi1, Roger R Beerli, Monika Bauer, Vania Manolova, Klaus Dietmeier, Regula B Buser, Thomas M Kündig, Philippe Saudan, Martin F Bachmann.   

Abstract

BACKGROUND: Allergen-specific desensitization (SIT) is the most effective therapy for allergies. Although allergen-specific antibodies have an important role in the process, mechanisms of IgG-mediated inhibition of allergic reactions are not well defined.
OBJECTIVE: We investigated mechanisms by which SIT-induced allergen-specific IgGs inhibit allergic reactions.
METHODS: We generated mAbs that recognize 3 nonoverlapping epitopes of the major cat allergen Fel d 1. Each of the mAbs was produced as an IgE and different IgG isotype.
RESULTS: IgEs against 2 nonoverlapping epitopes on Fel d 1 are necessary and sufficient to sensitize mast cells for maximal FcepsilonRI signaling and degranulation on exposure to monomeric Fel d 1. IgE antibodies of a third specificity did not further increase mast cell degranulation, indicating that formation of large FcepsilonRI clusters are not required to induce maximal activation of mast cells. A single IgG that was specific for an epitope different from those recognized by the IgEs was a potent inhibitor of Fel d 1-mediated mast cell activation in vitro and in vivo. This inhibition required Fcgamma receptor-IIB. In human beings, IgGs of a single specificity were able to block degranulation of basophils from individuals with cat allergy. The inhibitory potential of these antibodies increased when larger allergen-IgG complexes were formed.
CONCLUSIONS: These data reconcile conflicting theories in the literature and might explain the reason IgE levels do not necessarily decrease during therapy, despite clinical efficacy. These findings have important implications for vaccine design. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20624641     DOI: 10.1016/j.jaci.2010.05.040

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  26 in total

Review 1.  State-of-the-art review about basophil research in immunology and allergy: is the time right to treat these cells with the respect they deserve?

Authors:  Salvatore Chirumbolo
Journal:  Blood Transfus       Date:  2011-12-21       Impact factor: 3.443

2.  The safety and efficacy of sublingual and oral immunotherapy for milk allergy.

Authors:  Corinne A Keet; Pamela A Frischmeyer-Guerrerio; Ananth Thyagarajan; John T Schroeder; Robert G Hamilton; Stephen Boden; Pamela Steele; Sarah Driggers; A Wesley Burks; Robert A Wood
Journal:  J Allergy Clin Immunol       Date:  2011-11-30       Impact factor: 10.793

3.  Anti-FcεR1 antibody injections activate basophils and mast cells and delay Type 1 diabetes onset in NOD mice.

Authors:  Marc P Hübner; David Larson; Marina N Torrero; Ellen Mueller; Yinghui Shi; Kristin E Killoran; Edward Mitre
Journal:  Clin Immunol       Date:  2011-08-23       Impact factor: 3.969

Review 4.  Immunological mechanisms for desensitization and tolerance in food allergy.

Authors:  Rima Rachid; Dale T Umetsu
Journal:  Semin Immunopathol       Date:  2012-07-21       Impact factor: 9.623

5.  Prolonged ingestion of ovalbumin diet by sensitized mice improves the metabolic consequences induced by experimental food allergy.

Authors:  N V Batista; R V S Pereira; M L M Noviello; L P A Dourado; D A Perez; G Foureaux; A J Ferreira; A V M Ferreira; D C Cara
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 6.  Immunology in the Clinic Review Series; focus on allergies: basophils as biomarkers for assessing immune modulation.

Authors:  S U Patil; W G Shreffler
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 7.  Future therapies for food allergy.

Authors:  Laurie M McWilliams; Talal Mousallem; A Wesley Burks
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

Review 8.  Recombinant allergens: the present and the future.

Authors:  Marek Jutel; Katarzyna Solarewicz-Madejek; Sylwia Smolinska
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 9.  Novel developments in the mechanisms of immune tolerance to allergens.

Authors:  Thomas Eiwegger; Saskia Gruber; Zsolt Szépfalusi; Cezmi A Akdis
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

10.  A Single Monoclonal Antibody against the Peanut Allergen Ara h 2 Protects against Systemic and Local Peanut Allergy.

Authors:  Federico Storni; Gustavo Cabral-Miranda; Elisa Roesti; Lisha Zha; Paul Engeroff; Andris Zeltins; Mark Cragg; Monique Vogel; Martin F Bachmann
Journal:  Int Arch Allergy Immunol       Date:  2020-03-10       Impact factor: 2.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.